International eye-care products manufacturer Allergan announced positive outcomes from the AbbVie company’s Phase 3 study of a new treatment for presbyopia, as the ophthalmic solution AGN-190584 met primary and key secondary endpoints.
Antibodies triggered by Sinovac Biotech’s Covid-19 vaccine decline below a key threshold from around six months after a second dose for most recipients, although a third shot could have a strong boosting effect, according to a lab study.
BioNTech SE on July 26 announced the launch of the company’s Malaria project, which aims to develop a well-tolerated and highly effective Malaria vaccine and implement sustainable vaccine supply solutions on the African continent.
People who received the one-dose Johnson & Johnson Covid-19 vaccine may need a booster shot to fend off some of the worrisome coronavirus variants now spreading worldwide, a study suggests.
For many people, cats are cuddly and curious companions, but for at least 10 percent of adults they mean itchy skin, watering eyes and sneezing. This is primarily due to a protein called Fel d 1, and scientists are using a variety of approaches to try to change it.
Pfizer announced a second collaboration agreement with Arvinas to develop and commercialize the Connecticut-based company’s PROTAC estrogen receptor protein degrader.
Switzerland-based Roche is in talks with the U.S. Food and Drug Administration over the company’s Alzheimer’s drug candidate gantenerumab, which is being evaluated in clinical studies with a large-scale Phase III trial expected to wrap in the second half of 2022.
Two doses of Pfizer or AstraZeneca’s Covid-19 vaccine are nearly as effective against the highly transmissible Delta coronavirus variant as they are against the previously dominant Alpha variant, a study published on July 21 showed.
The U.S. Food and Drug Administration greenlit the classification of California-based biotechnology firm Genentech’s Venclexta (venetoclax) and azicitidine combination as a Breakthrough Therapy Drug.
Shares of Magenta Therapeutics were down after the company announced the U.S. Food and Drug Administration placed a clinical hold on its clinical program for acute myeloid leukemia and myelodysplastic syndrome.
